| Sign In to gain access to subscriptions and/or personal tools. |
Skeletal Muscle Susceptibility to Clofibrate Induction of Lesions in RatsToxicology Laboratory, Mitsubishi Pharma Corporation, Chiba 292-0818, Japan Correspondence: Address correspondence to: Miyoko Okada, Mitsubishi Pharma Corporation, 1-1-1, Kazusakamatari, Kisarazu, Chiba 292-0818, Japan; e-mail:Okada.Miyoko{at}mg.m-pharma.co.jp
Morphological changes induced by clofibrate in type-1 predominant soleus, type-2 predominant tensor fasciae latae, and type-1 and -2 mixed biceps femoris muscles and diaphragm in rats were investigated. Administration of the agent at 500 or 750 mg/kg/day by oral gavage for 14 or 28 days caused lesions in the soleus muscle and diaphragm, bur no changes in the tensor fasciae latae and biceps femoris muscles. In soleus muscle, vacuolation of muscle fibers was observed in all animals treated with clofibrate, and degeneration of muscle fibers and infiltration of leukocytes were noted at 750 mg/kg/day. In diaphragm, vacuolation of muscle fibers was also observed in all animals treated with clofibrate, and these lesions were located in type-1 skeletal muscles densely stained with NADH-TR. The vacuoles seen in soleus muscle and diaphragm were positive for oil red O staining. In addition, increase of lipid droplets and mitochondrial hypertrophy was seen in soleus muscle, ultrastructurally. These data suggest that sensitivity to clofibrate-induced muscle toxicity differs among muscles, with type-1 fibers being susceptible.
Key Words: Clofibrate • rat • muscle • myopathy • type-1 • mitochondria
Hyperlipidemia is a major risk factor for cardio- and cerebrovascular disease and therefore hypolipidemic drugs such as fibrates and statins have found wide application. These are generally considered safe and well tolerated (Johnson et al., 2005).
Fibrates are effective at lowering elevated plasma triglycerides by activation of the nuclear receptor peroxisome proliferator-activated receptor- HMG-CoA reductase inhibitors, statins, are also assosicated with skeletal myopathy (Evans and Rees 2002a, 2002b; Hodel, 2002; Thompson et al., 2003). Schaefer et al. (2004) previously reported induction skeletal myopathy in type-2 muscle fibers of rats by cerivastatin. They also described mitochondrial alteration, including disorganized cristae, flocculent matrix material, and membranous whorls in myofibers with degeneration. However, only few details has been reported regarding the myopathy induced by fibrates in animals (Teravainen et al., 1977; Afifi et al., 1984). In the present study, we therefore investigated morphological changes in rat skeletal muscles induced by clofibrate histologically and ultrastructurally. For this purpose, type-1 predominant soleus, type-2 predominant tensor fasciae latae, and type-1 and -2 mixed biceps femoris muscles and diaphragm were selected for examination.
Animals Female Crl:CD(SD) rats aged 5 weeks were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan) and acclimatized for 1 week in an air-conditioned animal room at 22°C with a 12-hour light/dark cycle. The animals were given CRF-1 (Oriental Yeast Co., Ltd, Tokyo, Japan) and tap water ad libitum.
Dosing
Necropsy and Tissue Collection
Light Microscopy
Electron Microscopy All experiments were performed under protocols approved by the Institutional Animal Care and Use Committee of Mitsubishi Pharma Corporation.
Microscopically, clofibrate-related changes with vacuolation of muscle fibers were noted in the soleus muscle and diaphragm of all treated animals (Figure 1). In contrast, no morphological alterations were apparent tensor fasciae latae and biceps femoris muscles. In the diaphragm, the lesions were located in type-1 skeletal muscles densely stained with NADH-TR (Figure 2). The vacuoles seen in soleus muscle and diaphragm were positive for oil red O staining (Figure 2).
Additionally, in the soleus muscle, degeneration of muscle fibers and infiltration of leukocytes were noted in rats treated with clofibrate at 750 mg/kg/day for 14 days or 28 days (Figure 3). Myofiber vacuolation was widespread in the soleus and diaphragm, whereas degenerative myofibers were focal and affected lesser numbers of myofibers and only in the soleus.
Ultrastructurally, increase of lipid droplets and hypertrophy of mitochondria were also seen in the soleus muscle (Figure 4). The microscopic change of muscular vacuolation corresponded with increase of lipid droplets.
In the present study, clofibrate was found to induce lesions limited to type-1 predominant soleus muscle, and type-1 muscle fibers in diaphragm of rats. Degeneration, increase of lipid droplets, and mitochondrial hypertrophy were observed. However, in type-2 predominant tensor fasciae latae muscle, and type-2 muscle fibers in diaphragm, no morphological changes were observed. These data clearly indicate that the sensitivity to clofibrate-induced muscle toxicity differs among the muscles. In contrast, one of the statins, cerivastatin, is known to induce skeletal myopathy involving type-2 muscle fibers of rats (Schaefer et al., 2004). From these data, the mechanisms of muscle toxicity caused by fibrates and statins may differ from each other.
The target muscle fibers may offer clues in this regard. Clofibrate-induced myopathy located in type-1 muscle fibers may be related to the drug efficacy and its effects on PPAR In the present study, mitochondrial hypertrophy and increase of lipid droplet were noted in soleus muscle. Similar lesions have been described in carnitine deficiency and zidovudine-induced myopathy in humans, these muscular disorders being considered correlated with mitochondrial impairment (Boudin et al., 1976; Dalakas et al., 1994; Mascaro et al., 1998). It has been reported that fibrates are effective in lowering elevated plasma triglycerides, but also induces mitochondrial dysfunction (Brunmair et al., 2004). Therefore, mitochondrial dysfunction might be one of causes of clofibrate-induced myopathy. Recently, it was reported that clofibrate-induced myopathy is related to carcium influx (Ikemoto and Endo, 2001; Matzno et al., 2006). Hodel briefly reviewed clofibrate-induced myopathy in rats (Hodel, 2002) but little concrete evidence has hitherto been available (Teravainen et al., 1977; Afifi et al., 1984).
We thank Hiroko Hirano and Jun-ichi Kashihara for their expert technical assistance.
Afifi, AK, Hajj, GA, Saad, S, Tekian, A, Bergman, RA, Bahuth, NB, & Abourizk, N. (1984). Clofibrate-induced myotoxicity in rats. Temporal profile of myopathology. Eur Neurol, 23, 182-97[Web of Science][Medline] [Order article via Infotrieve] Boudin, G, Mikol, J, Guillard, A, & Engel, AG. (1976). Fatal systemic carnitine deficiency with lipid storage in skeletal muscle, heart, liver and kidney. J Neurol Sci, 30, 313-25[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Brunmair, B, Lest, A, Staniek, K, Gras, F, Scharf, N, Roden, M, Nohl, H, Waldhausl, W, & Furnsinn, C. (2004). Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther, 311, 109-14 Dalakas, MC, Leon-Monzon, ME, Bernardini, I, Gahl, WA, & Jay, CA. (1994). Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol, 35, 482-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Evans, M, & Rees, A. (2002a). Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf, 25, 649-63[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Evans, M, & Rees, A. (2002b). The myotoxicity of statins. Curr Opin Lipidol, 13, 415-20[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Hodel, C. (2002). Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett, 128, 159-68[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Ikemoto, T, & Endo, M. (2001). Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br J Pharmacol, 134, 719-28[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Johnson, TE, Zhang, X, Shi, S, & Umbenhauer, DR. (2005). Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol, 208, 210-21[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Lane, RJ, & Mastaglia, FL. (1978). Drug-induced myopathies in man. Lancet, 2, 562-6[Web of Science][Medline] [Order article via Infotrieve] Mascaro, C, Acosta, E, Ortiz, JA, Marrero, PF, Hegardt, FG, & Haro, D. (1998). Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem, 273, 8560-3 Matzno, S, Yasuda, S, Kitada, Y, Akiyoshi, T, Tanaka, N, Juman, S, Shinozuka, K, Nakabayashi, T, & Matsuyama, K. (2006). Clofibrate-induced apoptosis is mediated by Ca2+-dependent caspase-12 activation. Life Sci, 78, 1892-9[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Russell, AP, Feilchenfeldt, J, Schreiber, S, Praz, M, Crettenand, A, Gobelet, C, Meier, CA, Bell, DR, Kralli, A, Giacobino, JP, & Deriaz, O. (2003). Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes, 52, 2874-81 Schaefer, WH, Lawrence, JW, Loughlin, AF, Stoffregen, DA, Mixson, LA, Dean, DC, Raab, CE, Yu, NX, Lankas, GR, & Frederick, CB. (2004). Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol, 194, 10-23[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Staels, B, Dallongeville, J, Auwerx, J, Schoonjans, K, Leitersdorf, E, & Fruchart, JC. (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98, 2088-93 Teravainen, H, Larsen, A, & Hillbom, M. (1977). Clofibrate-induced myopathy in the rat. Acta Neuropathol (Berl), 39, 135-8[CrossRef][Medline] [Order article via Infotrieve] Thompson, PD, Clarkson, P, & Karas, RH. (2003). Statin-associated myopathy. JAMA, 289, 1681-90 Warren, JD, Blumbergs, PC, & Thompson, PD. (2002). Rhabdomyolysis: a review. Muscle Nerve, 25, 332-47[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
Toxicologic Pathology, Vol. 35, No. 4,
517-520 (2007) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
Top
Abstract
Introduction
(PPAR
